Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

haematological cancer

- PMLiVE

MSD’s Keytruda plus chemotherapy approved in Scotland for advanced cervical cancer

There were around 604,000 new cases and 342,000 deaths in 2020 from cervical cancer

- PMLiVE

BMS and 2seventy bio report positive phase 3 results for multiple myeloma treatment

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

Endometrial cancer is the sixth most common cancer in women worldwide

- PMLiVE

Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP

At least 100 million people worldwide are impacted by some form of psoriasis

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

- PMLiVE

Merck’s Keytruda meets primary endpoint in phase 3 gastric cancer trial

Gastric cancer is the fourth leading cause of cancer death worldwide

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

BMS’s Reblozyl meets primary endpoint in myelodysplastic syndromes phase 3 trial

The study showed significant improvements in red blood cell transfusion independence

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

- PMLiVE

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival

- PMLiVE

Bristol Myers Squibb’s active ulcerative colitis treatment bags NICE recommendation

Phase 3 trial results of Zeposia showed statistically significant results in response and remission

- PMLiVE

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links